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Abstract The main objective of this work was to unequivocally 
determine the C-terminal sequence of human milk free secretory 
component (SC). It was found to end at arginine-585, i.e. 33 
amino acids downstream from the major heterogeneous C-
terminal residue previously identified for colostrum SC. In 
contrast, our data showed that the C-terminal end of SC was 
found to be homogeneous. Conflicting assignments, Asp/Gin, a 
missing Asn-211, Asp/Asn, Glu/Gln were corrected and found to 
agree with the cDNA sequence. An Ala/Val substitution at 
position 562 (domain VI) was identified. Its genetic significance 
is uncertain at present. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Secretory component (SC) is produced by cleavage of the 
polymeric Ig receptor during the transport of dimeric and 
polymeric IgAs into the secretions of the gastrointestinal, res-
piratory and genitourinary tracts. Dimeric and polymeric 
IgAs are synthesized by plasma cells present in mucosa-asso-
ciated lymphoid tissues and thus, need to be transported 
across the epithelia in order to perform their protective role 
against environmental antigens [1-3]. This is effected by bind-
ing of these IgAs to the poly-Ig receptor at the surface facing 
the mucosal tissues. After internalization, the complex is 
transported through the cell and inserted in the apical mem-
brane of the epithelium [4]. At that site, a still uncharacterized 
protease cleaves the poly-Ig receptor and releases SC bound to 
IgA [5-8]. This complex is known as slgA. The transcytosis of 
the poly-Ig receptor can occur independently of ligand bind-
ing and thus, free SC is also found in secretions [9]. 
Since it was discovered that SC was derived from the poly-
Ig receptor, efforts have been almost entirely focused on the 
biosynthesis and the transcytosis of the receptor [4]. Align-
ments of c D N A deduced amino acid sequences have revealed 
a high degree of homology between rabbit, human, rat, bovine 
"Corresponding author. Fax: (41-22) 702 55 02. 
Abbreviations: DTT, dithiothreitol; ES-MS, electrospray mass spec-
trometry; FAB-MS, fast atom bombardment mass spectrometry; 
PNGase F, peptide-W-glycosidase F; poly-Ig receptor, polymeric Ig 
receptor; RFLP, restriction fragment length polymorphism; SC, 
secretory component; slgA, secretory immunoglobulin A; TFA, 
trifluoroacetic acid; TPCK, tosyl-L-phenylalanine chloromethyl ketone 
and mouse poly-Ig receptors [8,10-15]. The extracellular por-
tion is composed of five Ig-like domains of 104-114 amino 
acids. The sixth, less related domain, contains the membrane 
spanning segment while the seventh domain is cytoplasmic. 
Ambiguities about the structure of SC itself, such as the lo-
cation of the exact extracellular cleavage site in the poly-Ig 
receptor, its primary sequence, and the type of oligosaccha-
rides present on the molecule, are still unresolved. F r o m car-
boxypeptidase Y digestion, it has been reported that the C-
terminal of rabbit SC was Ala-Glu [16]. By aligning sequences 
of domain VI from all known poly-Ig receptors, a highly 
conserved turn region followed by a stretch of 5 to 14 amino 
acids forming an alpha helix was disclosed [13]. A putative 
cleavage site was suggested in the middle of domain VI at the 
carboxyl side of Glu-589 in the human sequence [13]. In con-
trast, the primary structure of human SC disclosed that the C-
terminal was ragged and that the molecule was composed of a 
maximum of 558 amino acid residues [17,18]. 
Conflicts in the primary structure of human SC, not involv-
ing deamidation of predicted asparagine or glutamine resi-
dues, are still to be resolved (SWISS-PROT database acces-
sion number : P01833) . The availability of free SC from 
breast milk obtained from a single individual (M.W.) allowed 
us to unequivocally identify the C-terminal sequence of free 
SC, to correct 6 discrepancies between D N A and protein se-
quencing [11,12,17,18] and to suggest a mutat ion of Ala to 
Val at position 562 in the human sequence. 
2. Materials and methods 
2.1. Materials 
Sequencing-grade trypsin (EC 3.4.21.4), endoproteinase Glu-C (EC 
3.4.21.19) and peptide-/V-glycosidase F (EC 3.2.2.18) were purchased 
from Boehringer-Mannheim (Germany). Solvents for HPLC, dithio-
threitol and iodoacetic acid were from Merck, Darmstadt (Germany). 
Solvents used for sequencing were from Fluka, Buchs (Switzerland) 
and were further purified as described [19]. Water used was obtained 
from a Milli-Q water system (Millipore Corp., Bedford, MA). All 
other chemicals were of the best grade available. 
2.2. Purification of human SC 
Secretory component was purified from breast milk obtained from a 
single individual by a combination of gel nitration and ion-exchange 
chromatography as previously described [20]. 
2.3. Peptide mapping of SC tryptic and endoproteinase Glu-C peptides 
SC (1 mg) was fully reduced with a five-fold excess of DTT over 
cysteine content for 2 h at room temperature in 75 mM Tris-HCl, 6 M 
guanidine-HCl, pH 8.6. After reaction with a two-fold molar excess of 
iodoacetic acid (over DTT) for 30 min in the dark, the protein was 
dialyzed extensively against 0.5% ammonium bicarbonate and concen-
trated by vacuum centrifugation. Aliquots (0.2-0.4 mg) were incu-
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Fig. 1. Elution profile of a tryptic digest of human SC from whey of a single individual (M.W.). Tryptic peptides of fully reduced and carboxy-
methylated SC were applied to a RP300 reversed phase column (4.6X250 mm) equilibrated with aqueous 0.1% (w/v) TFA containing 3% (v/v) 
acetonitrile. A linear gradient of increasing acetonitrile concentration was applied at a flow rate of 0.7 ml/min and the effluent was monitored 
at 220 nm. Tryptic peptides of interest only were numbered according to their elution order. ♦ , peptides encompassing the carboxy-terminal re-
gion of SC. -w", glycopeptides present in SC; tryptic peptide T29 contains 2 glycosylation sites. Full structural elucidation of the oligosaccharide 
moieties will be presented elsewhere. • , discrepancies between predicted protein sequence from cDNA [11] and Eiffert et al. [17] protein se-
quence data. See also Table 1. 
bated at room temperature for 16 h with trypsin or endoproteinase 
Glu-C with an enzyme to protein ratio of 1 : 50 (w/w). Peptides were 
separated on a Brownlee RP300 reversed phase column (4.6x250 
mm) at a flow rate of 0.7 ml/min and were detected at 220 nm. Solvent 
A was 0.1% (w/v) TFA containing 3% (v/v) acetonitrile and solvent B 
was 0.08% (w/v) TFA in acetonitrile containing 8% (v/v) water. A 
linear gradient of 0 to 50% solvent B was applied during 90 min. If 
necessary, peptides of interest were further purified at a flow rate of 
150 Lil/min on a 2.1 X 100 mm HAIsil 300 C18 column (Higgins An-
alytical Inc.) equilibrated with a buffer consisting of 20 mM methyl-
phosphonic acid titrated to pH 6.9 with 12.5% trimethylamine. Linear 
gradients of either 0 to 30% or 0 to 40% of increasing acetonitrile 
concentration were applied during 30 min. Fractions from such chro-
matographic runs can be directly analyzed in an automated sequencer. 
2.4. Peptide-N-glycosidase F digestion 
PNGase F (0.5 mU) was added to individual purified glycopeptides 
and digestions were performed for 18 h at 37°C. Resulting products 
were purified using a C18 Sep-Pak cartridge: carbohydrates were 
eluted with 5% acetic acid and peptides were then released from the 
cartridge with 20% and 60% isopropanol in 5% acetic acid. 
2.5. Peptide characterization 
N-terminal sequence determination was carried out with a pulse-
liquid phase microsequencer, model 477A (Applied Biosystems, Foster 
City, CA) using standard programs. ES-MS was carried out using a 
VG Bio-Q mass spectrometer. FAB-MS was performed using a VG 
AutoSpect E mass spectrometer equipped with a Caesium ion gun 
operating at 30 kV at an emission of 1 uA [21]. 
3. Results 
A re-examination of the C-terminal structure of SC derived 
from human whey of a single individual (M.W.) was carried 
out. Fully reduced and carboxymethylated SC was digested 
with TPCK-treated trypsin, the digest was analysed by re-
versed phase H P L C (Fig. 1) and selected peptides were char-
acterised by partial N-terminal micro-sequencing and mass 
spectrometry, as detailed in Table 1. 
Three informative da ta are noteworthy from Table 1: 
(a) Peptides T5 (T7), Tigs, T4A, and Tg (or E2) constitute 
Table 1 
Analysis of tryptic and endoproteinase glu-C derived peptides from human SC by Edman degradation and mass spectrometry 
Proposed sequence ([11,12] Sequence from 
and this work) [17,18] 
HPLC fraction 
no. 
T34A 
T23 
T37 
T28B 
T24 
T5 
T7 
T19B 
T4A 
T9 
E2 
Calculated peptide 
mass 
2176 1 mono 
2044. l a T 
2241.5a v 
1858.1av 
1707.8av 
815.4m o n o 
8 4 3 4010110 
792 4 m o n o 
f.'i] ^mono 
6 9g4mono 
940.5mono 
ES-MS mass 
observed 
2176.3FAB 
2043.8 
2241.8 
1858.0 
1707.6 
815.5 
843.6 
792.2 
631.2 
698.2 
940.6 
Residue 
no. 
100-120 
194-212 
214-232 
233-250 
255-270 
560-567 
560-567 
568-574 
575-579 
580-585 
578-585 
GLSFDVSLEVSQGPGLLND118TK 
LSDAGQYLCQAGDDSNSN^K 
NAD^LQVLKPE^PEPELVYEDLR 
GSVTFHCALGPE244VANVAK 
QSSGENCD^VVVNTLGK 
ADA^APDEK 
ADV^APDEK 
VLDSGFR 
EIENK 
AIQDPR 
NKAIQDPR 
Q-118 
N-211 missing 
N-216, Q-223 
Q-244 
N-262 
Not found 
Not found 
Not found 
Not found 
Not found 
Not found 
Peptide designation is according to Fig. 1. T and E refer to tryptic and endoproteinase glu-C derived peptides, respectively. A or B following the 
tryptic peptide designation refers to peaks obtained from a reversed phase chromatographic run of the tryptic peptide fraction using a methyl-
phosphonic acid/trimethylamine buffer at pH 7.0. Residues underlined were determined by Edman sequencing and cysteine was observed as the 
carboxymethyl derivative. Calculated masses of peptides with MT under 1000 are monoisotopic (mono) and those for larger peptides studied with 
ES-MS are average values (av). The glycopeptide T34A was subjected to FAB-MS after treatment with PNGase F. Its monoisotopic mass was 
calculated taking into account the hydrolysis of the carbohydrate linked Asn at position 117 to an Asp residue. 
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Fig. 2. The carboxy-terminal sequence of human free secretory component. The sequence shown is that deduced from cDNA [11,12] encoding 
the human poly-Ig receptor. Carboxy-termini were reported to be at positions 550, 552, 558 and 559 with 552 being the major species [17]. Po-
sition 589 was predicted from an alignment of all known poly-Ig receptor sequences [8,13]. 
the carboxy-terminal region of secreted free human SC. Tryp-
tic peptide To., Ala-Ile-Gln-Asp-Pro-Arg, ends with Arg-585 
and peptide E2, generated upon Glu-C endoproteinase diges-
tion of SC, also terminates at position 585 (numbering of 
human SC according to SWISS-PROT database: accession 
number P01833). Thus, the C-terminal end of SC is located 
four residues upstream from the putative extracellular cleav-
age site at Glu-589 [8,13]. The data is at variance with that of 
Eiffert and collaborators who proposed ragged C-terminal 
tails at positions 559, 558, 552 and 550 [17,18]. 
(b) Our data agree with the cDNA nucleotide sequence 
[11,12] and we correct conflicting assignments reported 
[17,18] at positions Asp-118, Asn-211, Asp-216, Glu-223, 
Glu-244 and Asp-262 in pep tides T3 4A, T23, T37, T2SB and 
T24, respectively. 
(c) Both T5 and T7 peptides span positions 560-567; they 
differ from each other by an Ala/Val interchange at position 
562 and they were recovered in equal yield from the digest. 
Val-562 has not been detected at the cDNA level [12]. 
4. Discussion 
The physiological cleavage of the extracellular part of the 
poly-Ig receptor following transcytosis across epithelial cells 
leads to the release of SC, either free or bond to polymeric 
Igs. To date, the precise cleavage site is still ambiguous, as 
human SC was found to have a ragged C-terminus, varying 
from Ala-550 to Lys-559, with Ser-552 as the dominant C-
terminal residue [17,18]. On the basis of sequence homology 
among various animal species, a putative extracellular cleav-
age site was postulated to occur at the carboxyl side of Glu-
589 [8,13], in part, because of an unrealizable Ala-Glu C-
terminal sequence identified by carboxypeptidase Y digestion 
in rabbit SC [16]. 
Re-examination of the C-terminal structure of human SC 
from breast milk of a single individual unequivocally identifies 
Arg-585 as the C-terminus of secreted SC (Table 1), i.e. 33 
amino acids downstream from the major C-terminal residue 
determined for colostrum SC [17,18]. These data are summar-
ized in Fig. 2. 
Our data show that most if not all human SC molecules 
terminate at Arg-585, thus four residues upstream from the 
predicted putative physiological cleavage site of the poly-Ig 
receptor [8,10,13]. Whether the observed C-terminal Arg-585 
could have resulted from further exopeptidase processing, e.g. 
from Ala-588-Glu-589 after the release of free extracellular 
SC, cannot be excluded, but it appears unlikely for the follow-
ing reason: cleavage of the membrane associated poly-Ig re-
ceptor to soluble free SC was shown to be, at least partially, 
inhibited by leupeptin, known to bind to serine/cysteine pro-
tease active sites like trypsin [5,6]. Arg-585 appears, then, to 
be a compatible candidate as the true C-terminus of free hu-
man SC. In addition, Arg-585 is located in a predicted turn 
region, i.e. a section susceptible to proteolysis, in contrast to 
Ala-588-Glu-589 sequence, located within a hypothetical a-
helical structure [8], known to be generally resistant to cleav-
age unless unfolded [22]. The consensus putative cleavage site 
at Glu-589, based on sequence similarities among species may 
not be the universal physiological site, since experimental data 
have so far failed to prove that this in vivo site is correct. 
C-terminal sequences of SCs have been determined on rab-
bit, first [16], on human [17,18], and re-examined on human 
SC (this work). Rabbit and human SC C-terminal sequences 
differ [16] suggesting that distinct enzymatic specificities may 
be required for generating SCs from different species. Experi-
ments designed to test this hypothesis would be awaited with 
interest. 
Ala/Val interchange at position 562 is of interest because of 
possible allelic polymorphism detected in SC gene [12]. As the 
first polymorphic restriction site reported for PvuII was local-
ized in the third intron [23], it is irrelevant for the Ala/Val 
interchange cited above. A second Rsal RFLP fragment was 
described and could represent another polymorphism. How-
ever, none of the 10 theoretical Rsal fragments could account 
for Ala/Val change. Alternatively, a somatic point mutation 
(C for T) in Ala/Val codon cannot be ruled out. 
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